NAS:IDXX (USA) Also trade in: Austria Germany UK

IDEXX Laboratories Inc

$ 248.54 -1.02 (-0.41%)
Volume: 268,134 Avg Vol (1m): 476,826
Market Cap $: 21.38 Bil Enterprise Value $: 22.31 Bil
P/E (TTM): 56.12 P/B: 421.96
Earnings Power Value 29.04
Net Current Asset Value -10.64
Tangible Book -2.31
Projected FCF 37.97
Median P/S Value 107.6
Graham Number 0
Peter Lynch Value 82.13
DCF (FCF Based) 76.03
DCF (Earnings Based) 88.29
YTD (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.11
Cash-To-Debt ranked lower than
79.69% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
IDXX: 0.11
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.11, Med: 10.22, Max: 10000
Current: 0.11
0.11
10000
Equity-to-Asset 0.03
Equity-to-Asset ranked lower than
95.82% of 239 companies
in the Diagnostics & Research industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
IDXX: 0.03
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.07, Med: 0.77, Max: 0.9
Current: 0.03
-0.07
0.9
Debt-to-Equity 20.29
Debt-to-Equity ranked lower than
100.00% of 164 companies
in the Diagnostics & Research industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
IDXX: 20.29
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -633.99, Med: 0.03, Max: 129.54
Current: 20.29
-633.99
129.54
Debt-to-EBITDA 1.76
Debt-to-EBITDA ranked lower than
62.93% of 116 companies
in the Diagnostics & Research industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
IDXX: 1.76
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 0.53, Med: 1.53, Max: 3.15
Current: 1.76
0.53
3.15
Interest Coverage 15.11
Interest Coverage ranked lower than
66.26% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 15605.52, Med: 76.01, Min: 0.54
IDXX: 15.11
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 10.54, Med: 33.2, Max: 91.84
Current: 15.11
10.54
91.84
Piotroski F-Score 8
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 11.31
DISTRESS
GREY
SAFE
Beneish M-Score -2.30
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 47.97%
WACC 10.89%

Profitability & Growth : 9/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 22.71
Operating Margin ranked higher than
90.50% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
IDXX: 22.71
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 17.06, Med: 19.38, Max: 22.71
Current: 22.71
17.06
22.71
Net Margin % 17.33
Net Margin ranked higher than
86.31% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
IDXX: 17.33
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: 11.85, Med: 13.04, Max: 17.33
Current: 17.33
11.85
17.33
ROA % 25.17
ROA ranked higher than
93.13% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
IDXX: 25.17
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: 13.44, Med: 16.16, Max: 25.17
Current: 25.17
13.44
25.17
ROC (Joel Greenblatt) % 86.09
ROC (Joel Greenblatt) ranked higher than
89.96% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
IDXX: 86.09
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 53.83, Med: 65.41, Max: 92.36
Current: 86.09
53.83
92.36
3-Year Total Revenue Growth Rate 11.40
3-Year Revenue Growth Rate ranked higher than
72.53% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
IDXX: 13.5
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 8.4, Med: 14.1, Max: 35.6
Current: 13.5
8.4
35.6
3-Year Total EBITDA Growth Rate 15.70
3-Year EBITDA Growth Rate ranked higher than
68.54% of 178 companies
in the Diagnostics & Research industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
IDXX: 18
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -31.5, Med: 15.9, Max: 96.9
Current: 18
-31.5
96.9
3-Year EPS w/o NRI Growth Rate 27.60
3-Year EPS w/o NRI Growth Rate ranked higher than
62.58% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 138.7, Med: 10.1, Min: -301
IDXX: 27.6
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 16, Max: 50.4
Current: 27.6
0
50.4

» IDXX's 30-Y Financials

Financials (Next Earnings Date: 2019-08-01)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:IDXX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 325412    SIC : 2835
Compare NYSE:MTD XSWX:LONN NYSE:LH SHSE:603259 NYSE:A NYSE:WAT NYSE:DGX NAS:EXAS NYSE:IQV TSE:6869 XTER:SRT3 NAS:DXCM NYSE:PKI XPAR:BIM NYSE:BIO NYSE:QGEN XPAR:ERF NAS:ICLR NYSE:CRL NAS:PRAH
Traded in other countries IX1.Germany 0J8P.UK
Address One IDEXX Drive, Westbrook, ME, USA, 04092
IDEXX Laboratories Inc primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, laboratory equipment for blood-panel analysis, reference lab services, and tests to detect and manage disease in livestock. Idexx gets about 42% of its revenue from outside the United States.

Ratios

Current vs industry vs history
PE Ratio (TTM) 56.12
PE Ratio ranked lower than
83.19% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35, Min: 0.33
IDXX: 56.12
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 15.18, Med: 32.37, Max: 73.42
Current: 56.12
15.18
73.42
Forward PE Ratio 52.08
Forward P/E ranked lower than
97.50% of 40 companies
in the Diagnostics & Research industry.
Industry Max: 78.74, Med: 9999, Min: 11.64
IDXX: 52.08
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 56.12
PE without NRI ranked lower than
83.19% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35.56, Min: 0.34
IDXX: 56.12
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 15.18, Med: 32.37, Max: 73.42
Current: 56.12
15.18
73.42
Price-to-Owner-Earnings 73.50
Price-to-Owner-Earnings ranked lower than
75.00% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
IDXX: 73.5
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 21.36, Med: 35.76, Max: 75.79
Current: 73.5
21.36
75.79
PB Ratio 421.96
PB Ratio ranked lower than
100.00% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
IDXX: 421.96
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 3.87, Med: 7.94, Max: 852.86
Current: 421.96
3.87
852.86
PS Ratio 9.70
PS Ratio ranked lower than
71.74% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
IDXX: 9.7
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 1.75, Med: 4.21, Max: 10.68
Current: 9.7
1.75
10.68
Price-to-Free-Cash-Flow 83.74
Price-to-Free-Cash-Flow ranked lower than
76.25% of 80 companies
in the Diagnostics & Research industry.
Industry Max: 1356.19, Med: 29.22, Min: 0.35
IDXX: 83.74
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 13.01, Med: 35.75, Max: 84.69
Current: 83.74
13.01
84.69
Price-to-Operating-Cash-Flow 54.84
Price-to-Operating-Cash-Flow ranked lower than
82.47% of 97 companies
in the Diagnostics & Research industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
IDXX: 54.84
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 11.4, Med: 25.52, Max: 58.63
Current: 54.84
11.4
58.63
EV-to-EBIT 43.55
EV-to-EBIT ranked lower than
76.27% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
IDXX: 43.55
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 10.5, Med: 22.25, Max: 50.7
Current: 43.55
10.5
50.7
EV-to-EBITDA 37.42
EV-to-EBITDA ranked lower than
79.55% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
IDXX: 37.42
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 8.2, Med: 18.3, Max: 42.9
Current: 37.42
8.2
42.9
EV-to-Revenue 9.91
EV-to-Revenue ranked lower than
69.42% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
IDXX: 9.91
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 1.8, Med: 4.3, Max: 11
Current: 9.91
1.8
11
PEG Ratio 3.13
PEG Ratio ranked lower than
62.50% of 48 companies
in the Diagnostics & Research industry.
Industry Max: 128.13, Med: 3.26, Min: 0.32
IDXX: 3.13
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0.78, Med: 2.38, Max: 4.68
Current: 3.13
0.78
4.68
Shiller PE Ratio 108.86
Shiller PE Ratio ranked lower than
89.74% of 39 companies
in the Diagnostics & Research industry.
Industry Max: 459.08, Med: 52.49, Min: 10.19
IDXX: 108.86
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 26.11, Med: 51.29, Max: 126.39
Current: 108.86
26.11
126.39
Current Ratio 1.01
Current Ratio ranked lower than
89.60% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
IDXX: 1.01
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.85, Med: 2.89, Max: 8.34
Current: 1.01
0.85
8.34
Quick Ratio 0.74
Quick Ratio ranked lower than
89.20% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
IDXX: 0.74
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.62, Med: 2.03, Max: 7.55
Current: 0.74
0.62
7.55
Days Inventory 66.78
Days Inventory ranked higher than
54.41% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 917.88, Med: 79.76, Min: 0.37
IDXX: 66.78
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 63.41, Med: 81.19, Max: 89.55
Current: 66.78
63.41
89.55
Days Sales Outstanding 45.58
Days Sales Outstanding ranked higher than
75.49% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 521.64, Med: 67.51, Min: 1
IDXX: 45.58
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 37.43, Med: 41.47, Max: 45.58
Current: 45.58
37.43
45.58
Days Payable 26.08
Days Payable ranked lower than
84.49% of 187 companies
in the Diagnostics & Research industry.
Industry Max: 981.81, Med: 63.34, Min: 1
IDXX: 26.08
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 13.82, Med: 23.86, Max: 28.04
Current: 26.08
13.82
28.04

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate 1.40
3-Year Share Buyback Rate ranked higher than
98.89% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
IDXX: 1.4
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -21.4, Med: 2.2, Max: 6.2
Current: 1.4
-21.4
6.2

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 6.55
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
76.00% of 75 companies
in the Diagnostics & Research industry.
Industry Max: 449, Med: 2.41, Min: 0.47
IDXX: 6.55
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 1.49, Med: 2.63, Max: 6.93
Current: 6.55
1.49
6.93
Price-to-DCF (Earnings Based) 2.82
Price-to-Intrinsic-Value-DCF (Earnings Based) ranked lower than
70.59% of 17 companies
in the Diagnostics & Research industry.
Industry Max: 6.59, Med: 1.86, Min: 0.72
IDXX: 2.82
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
Price-to-Intrinsic-Value-DCF (Earnings Based) range over the past 10 years
Min: 1.06, Med: 2.3, Max: 3.74
Current: 2.82
1.06
3.74
Price-to-Median-PS-Value 2.31
Price-to-Median-PS-Value ranked lower than
87.56% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
IDXX: 2.31
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.42, Med: 0.89, Max: 2.43
Current: 2.31
0.42
2.43
Price-to-Peter-Lynch-Fair-Value 3.03
Price-to-Peter-Lynch-Fair-Value ranked lower than
83.33% of 30 companies
in the Diagnostics & Research industry.
Industry Max: 15.31, Med: 2.01, Min: 0.83
IDXX: 3.03
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.82, Med: 2.11, Max: 4.9
Current: 3.03
0.82
4.9
Earnings Yield (Joel Greenblatt) % 2.29
Earnings Yield (Greenblatt) ranked higher than
66.04% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
IDXX: 2.29
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 2, Med: 4.5, Max: 9.5
Current: 2.29
2
9.5
Forward Rate of Return (Yacktman) % 19.51
Forward Rate of Return ranked higher than
77.14% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 7802.99, Med: 8.45, Min: -35.9
IDXX: 19.51
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: 12.9, Med: 16.7, Max: 22.4
Current: 19.51
12.9
22.4

More Statistics

Revenue (TTM) (Mil) $ 2,251.64
EPS (TTM) $ 4.43
Beta 1.49
Volatility % 29.12
52-Week Range $ 176.11 - 256.22
Shares Outstanding (Mil) 86.1

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 8
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y